Inhibition of Snake Venom Serine Proteases Activities by Specific Antibody

Abstract

According to the World Health Organization, snake envenomation is a major neglected public health problem. In addition to deaths, these accidents cause other severe disabilities, such as amputations. Annually, around 2 million people worldwide are affected by snakebite, with Africa, Asia, and Latin America being the regions most affected. Snakes of the Bothrops genus are the main cause of snakebite accidents in Latin America. Serine proteases (SVSPs) are one of the main protein families that have been implicated in the alterations of the human hemostasis, which causes a tendency to increase thrombotic and hemorrhagic processes. Part of SVSPs, are thrombin-like enzymes (TLEs), which recognize and cleave human fibrinogen, but usually only releasing fibrinopeptide A or B and do not act on the coagulation Factor XIII. Consequently, these toxins contribute to coagulopathy by fibrinogen consumption, one of the major systemic hemostatic disturbances, frequently observed in snakebite victims. The bothropic antivenom is effective in reversing most of the systemic effects of envenomation when administered early in an adequate therapeutic dose. However, studies have demonstrated that, in some cases, antivenoms do not completely neutralize the action of SVSPs, which are co-responsible for systemic and local effects, such as coagulopathy and hemorrhage. In this context, a better understanding of SVSPs’ role in coagulopathy caused by envenomation, and developing new strategies to inhibit these toxins are important. To achieve this, we aimed in the current work to isolate an enriched pool of SVSPs from Bothrops jararaca and Bothrops atrox, to better understand the SVSPs’ interaction with murine monoclonal antibody (mAb) anti-SVSPs.